149 related articles for article (PubMed ID: 10048430)
1. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.
Zinzani PL; Magagnoli M; Frezza G; Prologo G; Gherlinzoni F; Bendandi M; Albertini P; Babini L; D'Alessandro R; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):571-6. PubMed ID: 10048430
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
[TBL] [Abstract][Full Text] [Related]
5. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
Sandlund JT; Murphy SB; Santana VM; Behm F; Jones D; Berard CW; Furman WL; Ribeiro R; Crist WM; Greenwald C; Chen G; Walter A; Pui CH
J Clin Oncol; 2000 Aug; 18(16):3018-24. PubMed ID: 10944136
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
7. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
van Besien K; Ha CS; Murphy S; McLaughlin P; Rodriguez A; Amin K; Forman A; Romaguera J; Hagemeister F; Younes A; Bachier C; Sarris A; Sobocinski KS; Cox JD; Cabanillas F
Blood; 1998 Feb; 91(4):1178-84. PubMed ID: 9454747
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
Haioun C; Besson C; Lepage E; Thieblemont C; Simon D; Rose C; Tilly H; Sonet A; Lederlin P; Attal M; Brière J; Reyes F
Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Bokstein F; Lossos A; Lossos IS; Siegal T
Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
11. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT.
Akkas BE; Vural GU
Nucl Med Commun; 2013 Jan; 34(1):50-6. PubMed ID: 23111376
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.
Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH
J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
Reman O; Pigneux A; Huguet F; Vey N; Delannoy A; Fegueux N; de Botton S; Stamatoullas A; Tournilhac O; Buzyn A; Charrin C; Boucheix C; Gabert J; Lhéritier V; Vernant JP; Fière D; Dombret H; Thomas X;
Leuk Res; 2008 Nov; 32(11):1741-50. PubMed ID: 18508120
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
[TBL] [Abstract][Full Text] [Related]
17. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
[No Abstract] [Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
